Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.

ABSTRACT:

Objective

To confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks, overall and according to diagnostic group.

Design

Prospective, double blind, superiority, randomised placebo controlled trial.

Setting

Seven French teaching hospitals between 13 April 2015 and 12 March 2019.

Eligibility criteria for participants

Aged 18 or older with current suicidal ideation, admitted to hospital voluntarily. Exclusion criteria included a history of schizophrenia or other psychotic disorders, substance dependence, and contraindications for ketamine.

Participants

156 participants were recruited and randomised to placebo (n=83) or ketamine (n=73), stratified by centre and diagnosis: bipolar, depressive, or other disorders.

Interv

SUBMITTER: Abbar M 

PROVIDER: S-EPMC8808464 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature